Skip to main content

GEMINI DRC Ph1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients with Geographic Atrophy (GA) Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103

Research Grant
Duke Scholars

Administered By

Ophthalmology

Awarded By

Gemini Therapeutics

Start Date

November 1, 2019

End Date

March 29, 2022
 

Administered By

Ophthalmology

Awarded By

Gemini Therapeutics

Start Date

November 1, 2019

End Date

March 29, 2022